Scott B. Perlman, MD close
Scott B. Perlman, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Scott B. Perlman, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Perlman is the Chief of the Division of Nuclear Medicine and Director of the UW PET Imaging Center. His research interests include PET imaging in oncology and the use of positron emision tomography to evaluate inflammatory disease. Dr. Perlman provides a wide range of nuclear medicine services, including general nuclear medicine, nuclear cardiology, BMD and PET scans.



Computerized Tomography (CT) Scan

Fluoroscopic Studies

Image-guided Biopsy

Magnetic Resonance Imaging (MRI) Scan

Nuclear Medicine





University Hospital
(608) 263-9729 | (800) 323-8942 | Map
Wisconsin Institutes for Medical Research
(608) 265-8231 | | Map

UW School of Medicine and Public Health

Department of Radiology

Professional Certifications and Education

Board Certification Nuclear Medicine
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School The Chicago Medical School, Chicago, IL

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Weisman AJ Kieler M Perlman S Hutchings M Jeraj R Kostakoglu Shields L Bradshaw TJ Comparison of 11 automated PET segmentation methods in lymphoma. Phys Med Biol . 2020 Sep 9;
[PubMed ID: 32906088]
Kyriakopoulos CE Heath EI Ferrari A Sperger JM Singh A Perlman SB Roth AR Perk TG Modelska K Porcari A Duggan W Lang JM Jeraj R Liu G Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. J Clin Oncol . 2020 Sep 8;:JCO2000348
[PubMed ID: 32897830]
Kusmirek JE Magnusson JD Perlman SB Current Applications for Nuclear Medicine Imaging in Pulmonary Disease. Curr Pulmonol Rep . 2020 Jul 22;:1-14
[PubMed ID: 32837866]
Hall LT Titz B Baidya N van der Kolk AG Robins HI Otto M Perlman SB Weichert JP Kuo JS [<sup>124</sup>I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors. Mol Imaging Biol . 2020 Apr;22(2):434-443
[PubMed ID: 31183841]
Roth AR Harmon SA Perk TG Eickhoff J Choyke PL Kurdziel KA Dahut WL Apolo AB Morris MJ Perlman SB Liu G Jeraj R Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer . 2019 Aug;17(4):306-314
[PubMed ID: 31221545]
Weisman AJ Harmon SA Perk TG Eickhoff J Choyke PL Kurdziel KA Dahut WL Humm JL Apolo AB Larson SM Morris MJ Perlman SB Liu G Jeraj R Quantification of bone flare on <sup>18</sup>F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis . 2019 May;22(2):324-330
[PubMed ID: 30413807]
Scarpelli M Zahm C Perlman S McNeel DG Jeraj R Liu G FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer . 2019 Jan 30;7(1):23
[PubMed ID: 30700328]
Lin C Harmon S Bradshaw T Eickhoff J Perlman S Liu G Jeraj R Response-to-repeatability of quantitative imaging features for longitudinal response assessment. Phys Med Biol . 2019 Jan 18;64(2):025019
[PubMed ID: 30566922]
Perk T Bradshaw T Chen S Im HJ Cho S Perlman S Liu G Jeraj R Automated classification of benign and malignant lesions in <sup>18</sup>F-NaF PET/CT images using machine learning. Phys Med Biol . 2018 Nov 20;63(22):225019
[PubMed ID: 30457118]
Perk T Chen S Harmon S Lin C Bradshaw T Perlman S Liu G Jeraj R A statistically optimized regional thresholding method (SORT) for bone lesion detection in <sup>18</sup>F-NaF PET/CT imaging. Phys Med Biol . 2018 Nov 20;63(22):225018
[PubMed ID: 30457117]
Scarpelli M Rampurwala M Eickhoff J Carmichael L Heideman J Binger K Kolesar J Perlman S Harrow K Dukart G Liang C Jeraj R Liu G Bruce JY Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol . 2018 Aug;82(2):211-219
[PubMed ID: 29802443]
Scarpelli M Simoncic U Perlman S Liu G Jeraj R Dynamic <sup>18</sup>F-FLT PET imaging of spatiotemporal changes in tumor cell proliferation and vasculature reveals the mechanistic actions of anti-angiogenic therapy. Phys Med Biol . 2018 Jul 27;63(15):155008
[PubMed ID: 29978839]
Scarpelli M Eickhoff J Cuna E Perlman S Jeraj R Optimal transformations leading to normal distributions of positron emission tomography standardized uptake values. Phys Med Biol . 2018 Jan 30;63(3):035021
[PubMed ID: 29235988]
Scarpelli M Bruce JY Carmichael L Eickhoff J Kolesar J Perlman S Jeraj R Liu G <sup>18</sup>F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemother Pharmacol . 2016 Dec;78(6):1245-1252
[PubMed ID: 27817059]
Lin C Bradshaw T Perk T Harmon S Eickhoff J Jallow N Choyke PL Dahut WL Larson S Humm JL Perlman S Apolo AB Morris MJ Liu G Jeraj R Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. J Nucl Med . 2016 Dec;57(12):1872-1879
[PubMed ID: 27445292]
Simoncic U Perlman S Liu G Jeraj R Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Nucl Med Commun . 2015 Dec;36(12):1174-80
[PubMed ID: 26378490]
Bruce JY Scully PC Carmichael LL Eickhoff JC Perlman SB Kolesar JM Heideman JL Jeraj R Liu G Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol . 2015 Jul;76(1):187-95
[PubMed ID: 26021741]
Simoncic U Perlman S Liu G Staab MJ Straus JE Jeraj R Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer . 2015 Feb;13(1):e7-e17
[PubMed ID: 25128349]
Muzahir S Jeraj R Liu G Hall LT Rio AM Perk T Jaskowiak C Perlman SB Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging . 2015;5(2):162-8
[PubMed ID: 25973337]
Lubner SJ Mullvain J Perlman S Pishvaian M Mortimer J Oliver K Heideman J Hall L Weichert J Liu G A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest . 2015;33(10):483-9
[PubMed ID: 26536061]